A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

Ivan de Kouchkovsky Arpit RaoBenedito A CarneiroLi ZhangCatriona LewisAudrey PhoneEric J SmallTerence W Friedlander Lawrence FongPamela L ParisCharles J RyanRussell Z SzmulewitzRahul Aggarwal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The combination of intermittent ribociclib plus every-3-weeks docetaxel demonstrated acceptable toxicity and encouraging efficacy in ARSI-pretreated mCRPC. Genomic profiling of CTCs may enrich for those most likely to derive benefit. Further evaluation in a randomized clinical trial is warranted.

Keyphrases

squamous cell carcinoma
small cell lung cancer
locally advanced
circulating tumor cells
cell cycle
oxidative stress
gene expression
high intensity
radiation therapy